Notification of Non-Substantial/Minor Amendments(s) for NHS Studies

This template **must only** be used to notify NHS/HSC R&D office(s) of amendments, which are **NOT** categorised as Substantial Amendments.

If you need to notify a Substantial Amendment to your study then you MUST use the appropriate Substantial Amendment form in IRAS.

Instructions for using this template

- For guidance on amendments refer to http://www.hra.nhs.uk/research-community/during-your-research-project/amendments/
- This template should be completed by the CI and optionally authorised by Sponsor, if required by sponsor guidelines.
- This form should be submitted according to the instructions provided for NHS/HSC R&D at <u>http://www.hra.nhs.uk/research-community/during-your-research-project/amendments/which-review-bodies-need-to-approve-or-be-notified-of-which-types-of-amendments/</u>. If you do not submit your notification in accordance with these instructions then processing of your submission may be significantly delayed.

Full title of study:	Prevention of Respiratory Insufficiency after Surgical Management (PRISM) Trial:		
	A pragmatic randomised controlled trial of continuous positive airway pressure (CPAP) to prevent respiratory complications and improve survival following major abdominal surgery		
IRAS Project ID:	183040		
Sponsor Amendment Notification number:	Minor amendment 2		
Sponsor Amendment Notification date:	05/08/2016		
Details of Chief Investigator:			
Name [first name and surname]	Rupert Pearse		
Address:	Adult Critical Care Unit		
	Royal London Hospital		
	Whitechapel		
	London		
	United Kingdom		
Postcode:	E1 1BB		
Contact telephone number:	+44 (0)20 3594 0351		
Email address:	r.pearse@qmul.ac.uk		
Details of Lead Sponsor:			

1. Study Information

Partner Organisations:					
Health Research Authority, England	NIHR Clinical Research Network, England				
NHS Research Scotland	NISCHR Permissions Co-ordinating Unit, Wales				
HSC Research & Development, Public Health Agency, Northern Ireland					
Name:	Queen Mary University London				
Contact email address:	sponsorsrep@bartshealth.nhs.uk				
Details of Lead Nation:					
Name of lead nation	England				
delete as appropriate					
If England led is the study going	Yes				
through CSP?					
delete as appropriate					
Name of lead R&D office:	Joint Research Management Office (QMUL, Bart's Health				
	NHS Trust)				

2. Summary of amendment(s)

This template **must only** be used to notify NHS/HSC R&D office(s) of amendments, which are **NOT** categorised as Substantial Amendments. If you need to notify a Substantial Amendment to your study then you MUST use the appropriate Substantial Amendment form in IRAS.

No.	Brief description of amendment (please enter each separate amendment in a new row)	Amendment applies to (delete/ list as appropriate)		List relevant supporting document(s), including version numbers (please ensure all referenced supporting documents are submitted with this form)		R&D category of amendment (category A, B, C) For office use only
		Nation	Sites	Document	Version	
1	Addition of sites	England	 All sites or list affected sites 1. Central Manchester University Hospitals NHS Foundation Trust 2. Stockport NHS Foundation Trust 3. Kings College London NHS Foundation Trust 4. University Hospitals of Morecambe Bay NHS Foundation Trust 	N/A	N/A	
		Northern	All sites or list affected sites			
		Ireland				
		Scotland	All sites or list affected sites			
		Wales	All sites or list affected sites			

3. Declaration(s)

Declaration by Chief Investigator

- I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility for it.
- I consider that it would be reasonable for the proposed amendment(s) to be implemented.

Signature of Chief Investigator:

Rupert Pearse

Print name: Professor Rupert Pearse

Date: 5th August 2016

Optional Declaration by the Sponsor's Representative (as per Sponsor Guidelines)

The sponsor of an approved study is responsible for all amendments made during its conduct.

The person authorising the declaration should be authorised to do so. There is no requirement for a particular level of seniority; the sponsor's rules on delegated authority should be adhered to.

• I confirm the sponsor's support for the amendment(s) in this notification.

Signature of sponsor's representative:

Print name:....

Post:

Organisation:....

Date:....